Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

The FDA has approved the first ever RNA interference drug – Alnylam’s Onpattro (patisiran) for the nerve damage caused by the rare disease hereditary transthyretin-mediated amyloidosis (hATTR ...

Ionis Pharmaceuticals’ RNA-targeted drug Waylivra has been conditionally approved in Europe for the devastating ultra-rare disease Familial Chylomicronemia Syndrome (FCS).

See the latest Alnylam Pharmaceuticals Inc stock price (ALNY:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Edit and preview flowcharts, sequence diagrams, gantt diagrams in real time. Save the result as a svg Get a link to a viewer of the diagram so that you can share it with others. Get a link to edit the ...